Dyadic to Present at World Vaccine Congress | Washington

Rhea-AI Summary

Dyadic International (Nasdaq: DYAI) has announced its participation in the 2025 World Vaccine Congress in Washington, D.C. CEO Mark Emalfarb will present on April 23, 2025, focusing on the company's C1 Platform and its application in addressing avian influenza (H5N1) and future pandemics.

The presentation, scheduled for 12:40 PM-1:10 PM in Room 202A, will showcase recent preclinical research utilizing Dyadic's proprietary C1 expression platform. The company will highlight data related to the production of non-mRNA antigens and reagents for vaccine production, demonstrating the platform's ability to elicit high neutralizing antibodies.

The C1 platform aims to enable rapid, cost-effective production of antigens, reagents, and cell culture media products to address global health challenges through scalable biomanufacturing. Interested parties can meet the management team at booth #654 or schedule meetings via assistant@dyadic.com.

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C.

World Vaccine Congress | Washington, D.C.
April 22–24, 2025
Presentation: Wednesday, April 23, 2025 | 12:40 PM–1:10 PM
Track: Influenza & Respiratory | Room 202A
Topic: C1 Platform: The Urgent Need for Smarter Biomanufacturing – A Call to Action on Avian Influenza (H5N1) & Future Pandemics

During the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic’s proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production.

“We are excited to share the latest pre-clinical data from multiple studies demonstrating that Dyadic’s proprietary C1 platform enables the production of non-mRNA antigens that elicit high neutralizing antibodies,” said Mr. Emalfarb. “Leveraging our C1 platform, we aim to enable rapid, cost-effective production of antigens, reagents and cell culture media products to address significant global health challenges, including avian influenza and future pandemics, through scalable and efficient biomanufacturing to meet the growing demand for rapid-response vaccines and therapeutics, paving the way for a more resilient global health infrastructure.”

Dyadic’s management team will be available for meetings throughout the conference. To schedule a meeting, please contact assistant@dyadic.com or visit booth #654 during the event.

About Dyadic International, Inc.

Dyadic International, Inc., is a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness.

Dyadic’s microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products.

For more information about Dyadic International, visit www.dyadic.com.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.

Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com

FAQ

What will Dyadic (DYAI) present at the 2025 World Vaccine Congress?

Dyadic will present their C1 Platform technology, focusing on biomanufacturing solutions for avian influenza (H5N1) and future pandemics, including data on non-mRNA antigens production.

When and where is Dyadic's presentation at the 2025 World Vaccine Congress?

The presentation is scheduled for Wednesday, April 23, 2025, from 12:40 PM to 1:10 PM in Room 202A, under the Influenza & Respiratory track.

What are the key benefits of Dyadic's C1 Platform for vaccine production?

The C1 Platform enables rapid, cost-effective production of antigens and reagents, producing non-mRNA antigens that elicit high neutralizing antibodies for efficient large-scale manufacturing.

How can investors meet with Dyadic's management team at the World Vaccine Congress?

Investors can schedule meetings by contacting assistant@dyadic.com or visiting booth #654 during the event.

What global health challenges does Dyadic's C1 Platform address?

The C1 Platform addresses challenges including avian influenza and future pandemics through scalable biomanufacturing for rapid-response vaccines and therapeutics.